HOLX

Hologic

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical Instruments & Supplies

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/07/26

Business Summary

Hologic generates cash by designing and selling specialized medical instruments and consumable supplies, particularly in diagnostics and women’s health, creating a blend of capital equipment sales and recurring revenue streams. The installed base of instruments drives ongoing demand for proprietary consumables, which supports revenue visibility and operating leverage. High switching costs in clinical environments create stickiness once hospitals and labs adopt its systems. Its moat is built less on raw scale and more on regulatory approvals, clinician trust, and embedded workflows that make displacement costly and operationally disruptive.

 


Analyze HOLX on TradingView

VALUATION

P/E

31.6

Market Cap ($M USD)

$16,968

Forward P/E

20.1

PEG

1.9

PRICE TO SALES

4.2

PRICE TO BOOK

3.2

EV / EBITDA

16

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$2.43

Next Year EPS Growth Estimate

$3.78

Next Year Revenue Growth Estimate

5.30%

Return on Equity (ROE)

10.40%

FREE CASH FLOW

Operating Margin

19.20%

Debt-to-Equity

0.5

Piotroski F-Score

6

Altman Z-Score

4.3

Return on Invested Capital (ROIC)

8.50%

Current Ratio

4

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze HOLX on TradingView

Gainseekers Quantitative Analysis

Summary

At 31.6x earnings with a Forward P/E of 20.1, the market is clearly pricing in an earnings normalization story, yet the 1.9 PEG suggests that growth is not coming cheap. The balance sheet is unquestionably stable with an Altman Z-Score of 4.3 and a Current Ratio of 4, eliminating near-term solvency concerns. However, a 5.30% Return on Equity and 8.50% ROIC are not elite metrics for a company trading above 20x forward earnings. This is not distressed, nor is it screamingly cheap; it’s a financially sound business priced for moderate growth execution, not a mispriced deep value opportunity.

AI Exposure / Tech Reliance

As a Medical Instruments & Supplies company in Healthcare, Hologic operates in a segment that is increasingly integrating AI into diagnostic imaging and workflow automation. The sector naturally benefits from data-driven diagnostics, which enhances equipment value and recurring usage. Its positioning within medical technology provides structural insulation from pure software disruption while allowing upside from AI-enabled diagnostic improvements.

The Bull Case

A GARP investor can justify ownership here based on financial durability and operational consistency. The company posts a 10.40% operating margin, 8.50% ROIC, and a Piotroski F-Score of 6, signaling fundamentally stable operations rather than financial engineering. Debt/Equity at 19.20% is conservative, and the Altman Z-Score of 4.3 confirms balance sheet strength, while institutional ownership at 75.58% suggests serious capital backing the story. With a Forward P/E of 20.1 versus a trailing 31.6, the market anticipates earnings normalization, and if EPS Next Year of $2.43 materializes cleanly, multiple compression risk diminishes. For investors seeking steady healthcare exposure without balance sheet stress, this profile offers disciplined growth with downside protection.

The Bear Case

The glaring issue is valuation relative to growth. A PEG of 1.9 combined with 5.30% ROE implies mediocre capital efficiency for a company trading at 31.6x earnings and 4.2x sales. Operating margins of 10.40% are respectable but not dominant in a medical technology business, and ROIC at 8.50% barely clears a reasonable cost of capital threshold. The absence of a meaningful dividend (0.5 TTM Yield, zero 5-year average growth) removes shareholder yield as a cushion, leaving investors dependent on execution. If growth disappoints, this multiple structure leaves limited room for error.

Market Sentiment & Smart Money

Short Interest %

3.70%

Analyst Consensus

3

Average Analyst Price Target

$75.58

Institutional Ownership %

96.50%

1-Year Beta

0.42

Insider Buying % (6 Mo)

0.80%%

Distance to 52-Week High

99.90%

Distance to 52-Week Low

146.50%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.